广东
分享至
瑞银发布报告指出，康方生物在研发和商业化方面取得显著进展，调高对公司近期产品销售增长和销售高峰的预测，将目标价从68.7港元上调至88.1港元，并重申“买入”评级。
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
